
    
      The purpose of this study is to assess the tolerability and safety include adverse events,
      vital signs, laboratory tests, etc., of a range of doses of chidamide combined with CHOP in
      peripheral T-cell lymphoma patients, and to determine the dose limit toxicity and the maximum
      tolerable dose.
    
  